C12N 2740/17043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2740/17043 (Viral genome or elements thereof as genetic vector) appears on 8 US grants and 16 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 16
- Assignees
- 14
- Inventors
- 34
- Latest grant
- 14 Nov 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 2 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 3 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Beta-2 microglobulin-deficient cells14 Nov 2023US 11,813,318 B2University of Washington
- RNA based method to obtain stably integrated retroviral vectors13 Aug 2019US 10,378,026 B2Cellectis
- Isolation of a human retrovirus5 Oct 2004US 6,800,475 B1The United States of America as represented by the Department of Health and Human Services
- Retrovirus isolated from humans7 Sep 2004US 6,787,333 B2The United States of America as represented by the Department of Health and Human Services
- Spumavirus isolated from humans23 Sep 2003US 6,623,952 B1The United States of America as represented by the Department of Health and Human Services
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Targeted retroviral integration for treatment of genetic disorders26 Dec 2024US 2024/0425828 A1Ohio State Innovation Foundation
- Beta-2 microglobulin-deficient cells27 Jun 2024US 2024/0207378 A1University of Washington through its Center for Commercialization
- Foamy viral vector compositions and methods for the manufacture of same24 Feb 2022US 2022/0056477 A1Children's Hospital Medical Center
- Foamy viral vector compositions and methods for the manufacture of same14 May 2020US 2020/0149065 A1Children's Hospital Medical Center
Most cited
By later US patents
- Recombinant foamy virus vectors for medicinal, and diagnostic uses, and processes for preparing recombinant foamy virus vectors13US 5,646,032 ABayer Aktiengesellschaft · 1997
- Retrovirus isolated from humans10US 5,882,912 ACenter for Disease Control and Prevention · 1999
- RNA based method to obtain stably integrated retroviral vectors4US 10,378,026 B2Cellectis · 2019